Compare BCBP & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BCBP | SPRO |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.1M | 156.3M |
| IPO Year | 2005 | 2017 |
| Metric | BCBP | SPRO |
|---|---|---|
| Price | $10.35 | $2.10 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 208.8K | ★ 1.6M |
| Earning Date | 04-21-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.10% | N/A |
| EPS Growth | N/A | ★ 111.81 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | ★ $66,802,000.00 |
| Revenue This Year | $85.26 | N/A |
| Revenue Next Year | $6.14 | $300.00 |
| P/E Ratio | $38.77 | ★ N/A |
| Revenue Growth | N/A | ★ 39.24 |
| 52 Week Low | $7.31 | $1.80 |
| 52 Week High | $11.71 | $3.08 |
| Indicator | BCBP | SPRO |
|---|---|---|
| Relative Strength Index (RSI) | 47.08 | 38.15 |
| Support Level | $7.61 | $1.93 |
| Resistance Level | $10.50 | $2.45 |
| Average True Range (ATR) | 0.35 | 0.11 |
| MACD | -0.09 | -0.00 |
| Stochastic Oscillator | 50.00 | 29.60 |
BCB Bancorp Inc is a bank holding company. The company offers loans, including commercial and multi-family real estate loans, home equity loans, construction loans, consumer loans, and commercial business loans; FDIC-insured deposit products, such as savings and club accounts, interest and non-interest bearing demand accounts, money market accounts, certificates of deposit and individual retirement accounts, and retail and commercial banking services, including wire transfers, money orders, safe deposit boxes, a night depository, debit cards, online banking, gift cards, fraud detection and automated teller services.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.